Inhibition of DUX4 Expression Using Bromodomain and Extra-Terminal Domain Protein Inhibitors (BETi)

• 收藏
• 分享

专利权人:

发明人:

Francis M. Sverdrup

申请号：

US15785095

公开号：

US20180050043A1

申请日:

2017.10.16

申请国别(地区):

US

年份:

2018

代理人:

摘要：

The use of BETi as a potential treatment for FSHD is provided. Specifically, the use of BETi, and particularly selective BETi for BRD4, are shown to inhibit DUX4 expression which is expected to result in a decrease in the severity of symptoms of FSHD. Further, the treatments are shown to work when pulsed as opposed to continuous. This allows for a BETi to be supplied to a human in a pulse, and then allows the human to not need any additional treatment for a window at least as long as the one of the treatment pulse.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/